NHWD-870 HCl achieves 45% response rate in thoracic NUT carcinoma, nearly doubling the overall cohort's 30% rate in advanced...

Tarlatamab plus durvalumab cuts death risk 58% in first-line small cell lung cancer, extending median overall survival to 21.1...

Tango Therapeutics updates vopimetostat Phase 1/2 Trial results in combination with RAS(ON) inhibitors. Full data available in SEC filing.

Perspective Therapeutics' lead-212 radiopharmaceutical shows responses in neuroendocrine tumor trial, with interim Phase 1/2a data presented at European nuclear

Upacicalcet meets primary endpoints in Phase 3 trials for secondary hyperparathyroidism, with 42–44% of patients achieving 30% PTH reduction...

Sefaxersen achieves 43% proteinuria reduction in Phase 3 IgA Nephropathy Study, targeting disease mechanisms beyond standard care in kidney...

Lilly's sofetabart mipitecan achieves 79% response rate in platinum-sensitive ovarian cancer patients, including those with prior PARP inhibitor exposure.

FDA approves subcutaneous SKYRIZI for Crohn's disease induction, allowing at-home treatment. Phase 3 data showed 74% of biologic-naive patients...

A Lancet Psychiatry cohort of 70,257 schizophrenia patients shows GLP-1 agonists reduce acute psychiatric care. Trial design hasn't caught...

eClinical Solutions appoints three C-suite executives to lead product, finance, and talent functions amid strong first-half momentum and market...